BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 19184068)

  • 1. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention.
    Iqbal K; Grundke-Iqbal I
    J Cell Mol Med; 2008; 12(1):38-55. PubMed ID: 18194444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.
    Iqbal K; Alonso AC; Gong CX; Khatoon S; Pei JJ; Wang JZ; Grundke-Iqbal I
    J Neural Transm Suppl; 1998; 53():169-80. PubMed ID: 9700655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach.
    Iqbal K; Alonso AD; Gondal JA; Gong CX; Haque N; Khatoon S; Sengupta A; Wang JZ; Grundke-Iqbal I
    J Neural Transm Suppl; 2000; 59():213-22. PubMed ID: 10961432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion.
    Iqbal K; Alonso Adel C; El-Akkad E; Gong CX; Haque N; Khatoon S; Pei JJ; Tsujio I; Wang JZ; Grundke-Iqbal I
    J Mol Neurosci; 2002; 19(1-2):95-9. PubMed ID: 12212801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau in Alzheimer disease and related tauopathies.
    Iqbal K; Liu F; Gong CX; Grundke-Iqbal I
    Curr Alzheimer Res; 2010 Dec; 7(8):656-64. PubMed ID: 20678074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays.
    Iqbal K; Alonso Adel C; El-Akkad E; Gong CX; Haque N; Khatoon S; Pei JJ; Tanimukai H; Tsujio I; Wang JZ; Grundke-Iqba I
    J Mol Neurosci; 2003; 20(3):425-9. PubMed ID: 14501027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies.
    Vingtdeux V; Davies P; Dickson DW; Marambaud P
    Acta Neuropathol; 2011 Mar; 121(3):337-49. PubMed ID: 20957377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological approaches of neurofibrillary degeneration.
    Iqbal K; Grundke-Iqbal I
    Curr Alzheimer Res; 2005 Jul; 2(3):335-41. PubMed ID: 15974899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly.
    Iqbal K; Alonso Adel C; Grundke-Iqbal I
    J Alzheimers Dis; 2008 Aug; 14(4):365-70. PubMed ID: 18688085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer's disease and other tauopathies.
    Iqbal K; Grundke-Iqbal I
    Curr Drug Targets; 2004 Aug; 5(6):495-502. PubMed ID: 15270196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.
    Alonso Adel C; Li B; Grundke-Iqbal I; Iqbal K
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8864-9. PubMed ID: 16735465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration.
    Iqbal K; Alonso Adel C; El-Akkad E; Gong CX; Haque N; Khatoon S; Tsujio I; Grundke-Iqbal I
    J Neural Transm Suppl; 2002; (62):309-19. PubMed ID: 12456074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial.
    Iqbal K; Wang X; Blanchard J; Liu F; Gong CX; Grundke-Iqbal I
    Biochem Soc Trans; 2010 Aug; 38(4):962-6. PubMed ID: 20658985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
    Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
    Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau.
    Alonso AD; Grundke-Iqbal I; Barra HS; Iqbal K
    Proc Natl Acad Sci U S A; 1997 Jan; 94(1):298-303. PubMed ID: 8990203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.